Congress expands fentanyl sanctions, but gives president 5-year waiver power

What it does

This bill expands U.S. sanctions authority to target foreign governments and officials involved in chemical or biological weapons programs—including fentanyl precursor production—that harm other countries. It requires the President to impose escalating sanctions (export controls, aid cuts, financial freezes) on countries whose officials commit such acts, with a mandatory 60-day determination window and a tiered sanction regime over 210 days, though the President may waive sanctions for up to 5 years if national security requires it.

Why we flagged it

The bill's core function is to expand presidential authority to impose sanctions on foreign governments and officials involved in chemical/biological weapons programs and fentanyl precursor production. It is a foreign policy and national security measure, not a domestic regulatory or appropriations bill.

What the text implies

• The definition of 'covered act' includes fentanyl precursor production (benzylfentanyl, 4-anilinopiperidine, norfentanyl precursors), effectively weaponizing sanctions authority against drug trafficking—a novel expansion of CBW law into narcotics control that may blur lines between national security and drug enforcement.
• The President's waiver authority is renewable indefinitely for 180-day periods until 5 years post-enactment, creating a long window during which sanctions can be suspended without congressional override, potentially allowing geopolitical considerations to override the bill's stated public-health purpose.
• The 'foreign governmental entity' definition is broad and includes entities that 'receive significant material support' from a government and engage in commercial services or manufacturing—potentially capturing private contractors, suppliers, and intermediaries, not just state actors.
• Sanctions on 'all scientific cooperative programs' may disrupt legitimate academic and public-health collaboration (e.g., disease surveillance, vaccine research) with targeted countries, creating collateral damage to global health infrastructure.
• The bill requires no explicit congressional approval for sanctions escalation; the President reports to Congress at 120 and 210 days, but Congress has no affirmative power to block or modify sanctions—only the President can terminate them after 1 year if conditions are met.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens U.S. tools to combat transnational chemical/biological threats (including fentanyl trafficking), which benefits public health and security. However, the broad definition of "covered act" and the President's discretionary waiver authority (renewable for 5 years) create risk that sanctions may be applied inconsistently or withheld for geopolitical reasons unrelated to the stated harm, undermining transparency and predictability in foreign policy.

Who stands to gain

• U.S. defense and export-control contractors (benefiting from expanded enforcement and compliance inf
• U.S. pharmaceutical and chemical manufacturers (protected from competition via export controls on ta

Named in the bill

Chemical and Biological Weapons Control and Warfare Elimination Act of 1991, Biological Weapons Convention, Chemical Weapons Convention, Export Administration Regulations, Commerce Control List, Bureau of Industry and Security, Department of Commerce, Arms Export Control Act, Atomic Energy Act of 1954, Export Control Reform Act of 2018, Foreign Assistance Act of 1961, National Security Act of 1947 — and 2 more

Where it stands

2 cosponsors: 2 Republicans.

• Jan 9, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 9, 2025 — Referred to Senate Committee on Foreign Relations · Congress.gov: “Read twice and referred to the Committee on Foreign Relations”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $290,000 in lobbying spend. A filing names 89 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Jim Banks, the sponsor, reported $559,626 in PAC receipts in the 2026 cycle.

• Fdd Action — $290,000 on 1 filing

Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.